Market Place
Sourcing Support
Merlin CP-GEP Predicts Sentinel-Node Metastasis in Early Melanoma
25 Mar 2026 //
PR NEWSWIRE
SkylineDx Launches SLNB Initiative Targeting Early-Stage Melanoma
05 Mar 2026 //
PR NEWSWIRE
Merlin CP-GEP Added to NCCN Melanoma Guide
19 Feb 2026 //
PR NEWSWIRE
SkylineDx: Merlin CP-GEP Leads in Melanoma Risk Assessment
18 Dec 2025 //
PR NEWSWIRE
Skylinedx Validate Merlin CP-GEP Test In Melanoma In JAMA Surgery
22 Oct 2025 //
PR NEWSWIRE
SkylineDx`s Merlin Melanoma Assay cuts SLNB by over 40%
22 Jul 2025 //
PR NEWSWIRE
SkylineDx`s Merlin CP-GEP Assay Precisely Stratify Biopsy Patient
09 Jul 2025 //
PR NEWSWIRE
SkylineDx Presents CP-GEP Merlin Test Data
11 Oct 2024 //
PR NEWSWIRE
SkylineDx & NeraCare enter a strategic partnership to advance precision medicine
20 Apr 2023 //
PR NEWSWIRE
Independent validation of performance Merlin Test in Swedish patients
24 Mar 2022 //
PRNEWSWIRE
SkylineDx and VIB enter a strategic partnership in molecular diagnostics
22 Dec 2021 //
PRNEWSWIRE
SkylineDx and VIB enter a strategic partnership in molecular diagnostics
21 Dec 2021 //
PRNEWSWIRE
SkylineDx launches US prospective melanoma trial to validate Merlin Assay
10 Jun 2021 //
PRNEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.